---
layout: post
title: "Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers; Revised Draft Guidance for Industry; Availability"
date: 2026-02-05 19:00:25 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-18083
original_published: 2022-08-23 00:00:00 +0000
significance: 8.00
---

# Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers; Revised Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** August 23, 2022 00:00 UTC
**Document Number:** 2022-18083

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled "Charging for Investigational Drugs Under an IND: Questions and Answers." Since issuance of the final guidance in 2016, FDA has received questions from stakeholders through the docket and in the form of communications with review divisions. These questions relate to the implementation of FDA's regulation on charging for investigational drugs under an investigational new drug application (IND) for the purpose of either clinical trials or expanded access for treatment use. FDA is providing this revised draft guidance in a question-and-answer format, addressing the most recently asked questions. When finalized, this revised draft guidance will replace the final guidance of the same title issued in June 2016.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/08/23/2022-18083/charging-for-investigational-drugs-under-an-investigational-new-drug-application-questions-and)
- API: https://www.federalregister.gov/api/v1/documents/2022-18083

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
